Addex Therapeutics (ADXN) announced that following the previously announced termination of development of ADX71149 in epilepsy, its partner Janssen Pharmaceuticals (JNJ) has returned all development and commercialization rights to ADX71149 and the partnership between the two companies has been terminated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.